Suppr超能文献

监测凝血酶原时间/国际标准化比值不可靠患者的抗凝情况:II 因子与显色法 X 因子检测对比

Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing.

作者信息

Baumann Kreuziger Lisa M, Datta Yvonne H, Johnson Andrew D, Zantek Nicole D, Shanley Ryan, Reding Mark T

机构信息

aDivision of Hematology, Oncology, and Transplantation, University of Minnesota bDepartment of Laboratory Medicine and Pathology, University of Minnesota cCTSI Biostatstics, University of Minnesota, Minneapolis, Minnesota, USA.

出版信息

Blood Coagul Fibrinolysis. 2014 Apr;25(3):232-6. doi: 10.1097/MBC.0000000000000030.

Abstract

The international normalized ratio (INR) can be unreliable in patients with lupus anticoagulants (LACs) or other conditions affecting baseline testing. Alternative methods to assess anticoagulation on warfarin through measures of vitamin K-dependent factor activity by clot based or chromogenic assays may be necessary. In this patient population, the ideal method is unknown. Thirty-six patients stable on warfarin with LAC or unreliable INR testing had an INR, a prothrombin time-based clotting assay for factor II (FII) activity, and a chromogenic assay for factor X (CFX) activity were performed simultaneously. Eighty-nine sets of measurements were obtained of which 83 sets included all three assays. CFX and FII levels were well correlated (r = 0.92) in all patients and in 26 patients with a documented antiphospholipid antibody (r = 0.93). Parallel testing was seen in 99% of FII assays. Sixty-one percent of CFX and 57% of FII were within the therapeutic range. In 32 CFX and FII pairs wherein assessment of anticoagulation was discordant, 16 CFX agreed with INR and 13 FII agreed with INR (McNemar's, χ = 0.14, P = 0.7). The number of times tests were discrepant was not statistically different between CFX and FII (P = 0.36). CFX and FII activity are well correlated in patients that require alternative monitoring of warfarin. Either test can be used in this population.

摘要

国际标准化比值(INR)在患有狼疮抗凝物(LAC)或其他影响基线检测的疾病的患者中可能不可靠。通过基于凝血或显色测定法测量维生素K依赖因子活性来评估华法林抗凝效果的替代方法可能是必要的。在这一患者群体中,理想的方法尚不清楚。36名服用华法林病情稳定但伴有LAC或INR检测不可靠的患者同时进行了INR、基于凝血酶原时间的因子II(FII)活性凝血测定以及因子X(CFX)活性显色测定。共获得89组测量值,其中83组包含所有三项检测。在所有患者以及26名有抗磷脂抗体记录的患者中,CFX和FII水平相关性良好(r = 0.92和r = 0.93)。99%的FII检测呈平行关系。61%的CFX和57%的FII处于治疗范围内。在32对CFX和FII检测结果不一致的抗凝评估中,16个CFX结果与INR一致,13个FII结果与INR一致(麦克尼马尔检验,χ = 0.14,P = 0.7)。CFX和FII检测结果出现差异的次数在统计学上无显著差异(P = 0.36)。在需要对华法林进行替代监测的患者中,CFX和FII活性相关性良好。这两种检测方法均可用于该患者群体。

相似文献

2
Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients.
Blood Coagul Fibrinolysis. 2010 Apr;21(3):242-4. doi: 10.1097/MBC.0b013e32833581a3.
4
Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant.
Ann Pharmacother. 2014 Nov;48(11):1479-83. doi: 10.1177/1060028014546361. Epub 2014 Aug 7.
5
Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy.
Biomed Pharmacother. 2010 Feb;64(2):130-2. doi: 10.1016/j.biopha.2009.09.020. Epub 2009 Dec 16.
9
Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome.
Ann Hematol. 2015 Aug;94(8):1291-9. doi: 10.1007/s00277-015-2374-3. Epub 2015 Apr 10.
10
Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy.
Blood Coagul Fibrinolysis. 2008 Sep;19(6):513-7. doi: 10.1097/MBC.0b013e328304e066.

引用本文的文献

1
Impact of thromboplastin reagents on monitoring INR in a patient with triple-positive antiphospholipid syndrome: a case report.
Front Immunol. 2025 Jul 31;16:1591029. doi: 10.3389/fimmu.2025.1591029. eCollection 2025.
2
A Patient with Recurrent Strokes: Approach to Coagulopathy.
TH Open. 2023 Sep 27;7(3):e262-e269. doi: 10.1055/a-2161-1262. eCollection 2023 Jul.
3
Homozygous Factor V Leiden Complicated by Heparin-Induced Thrombocytopenia: A Case Report.
J Med Cases. 2022 May;13(5):225-228. doi: 10.14740/jmc3914. Epub 2022 Apr 23.
4
Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2.
Blood Adv. 2020 Sep 8;4(17):4208-4216. doi: 10.1182/bloodadvances.2020002267.

本文引用的文献

2
Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients.
Blood Coagul Fibrinolysis. 2010 Apr;21(3):242-4. doi: 10.1097/MBC.0b013e32833581a3.
4
Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy.
Blood Coagul Fibrinolysis. 2008 Sep;19(6):513-7. doi: 10.1097/MBC.0b013e328304e066.
8
Monitoring warfarin therapy in patients with lupus anticoagulants.
Ann Intern Med. 1997 Aug 1;127(3):177-85. doi: 10.7326/0003-4819-127-3-199708010-00001.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验